Table 1.
Clinical Characteristic of the Subjects
| HC (n =25) | CHB (n =26) | HBV-LC (n =28) | HBV-DCC (n = 27) | HBV‐ACLF | ||||
|---|---|---|---|---|---|---|---|---|
| Total (n=185) | Deriving Cohort (n=120) | Validation Cohort (n=65) | P* | |||||
| Age (y) | 45.40±11.95 | 38.15±10.76 | 47.75±12.46 | 54.85±10.75 | 48.39±12.69bd | 48.68±13.61 | 47.86±10.86 | NS |
| Gender (female/male) | 8/17 | 7/19 | 7/21 | 9/18 | 27/158ad | 16/104 | 11/54 | NS |
| WBC (×109/L) | 6.63±1.48 | 5.51±1.68 | 4.13±1.86 | 2.86±1.52 | 7.11±4.56bcd | 7.11±4.08 | 6.56±3.25 | NS |
| Neutrophil (×109/L) | 3.64±1.08 | 2.86±1.09 | 2.19±1.04 | 2.53±4.67 | 4.95±3.38abcd | 5.11±3.66 | 4.64±2.81 | NS |
| Platelet (×109/L) | 207.00(190.00 −253.00) | 178.00(156.50–211.00) | 88.50(61.50–125.25) | 50.00(31.00–84.00) | 87.00(60.00–120.50)abd | 86.50(63.25–125.00) | 92.00 (56.00–115.00) | NS |
| Albumin (g/L) | 46.20±2.67 | 41.17±3.22 | 35.24± 5.66 | 28.40±5.87 | 29.74±4.84abc | 29.62±4.77 | 29.97±5.00 | NS |
| ALT (U/L) | 19.00(15.50–35.50) | 29.00(19.50–77.25) | 51.50(27.25–169.50) | 26.00(18.00–43.00) | 401.00(119.50–751.50)abcd | 403.50(130.25–768.25) | 355.00(112.00–715.00) | NS |
| AST (U/L) | 24.00(22.50–29.50) | 26.00(19.00–47.25) | 52.50(32.50–100.50) | 46.00(33.90–66.10) | 262.00(145.50–599.00)abcd | 263.50(157.00–611.50) | 228.00 (116.00–584.00) | NS |
| Serum bilirubin (mg/dL) | 0.83±0.21 | 0.94±0.76 | 1.57± 1.24 | 2.15±1.51 | 19.42±8.21abcd | 19.52±8.23 | 19.23±8.22 | NS |
| BUN (mmol/L) | 4.88(4.73–5.68) | 4.59(3.84–5.62) | 4.36(3.40–5.60) | 4.92(3.56–7.26) | 4.33(3.07–5.96) | 4.26(3.05–5.65) | 4.44 (3.32–6.16) | NS |
| Creatinine (mg/dL) | 0.78(0.62–0.94) | 0.76(0.64–0.88) | 0.67(0.51–0.76) | 0.86(0.53–1.02) | 0.84(0.70–1.02) | 0.84(0.70–1.02) | 0.83 (0.70–0.95) | NS |
| INR | 0.91(0.87–0.95) | 1.00(0.92–1.06) | 1.18(1.04–1.36) | 1.45(1.35–1.53) | 2.08(1.72–2.63)abcd | 2.17(1.78–2.64) | 2.01 (1.65–2.60) | NS |
| MELD | ND | ND | 5.01±3.70 | 10.61±5.05 | 24.90±6.80abcd | 25.49±6.87 | 24.51±6.49 | NS |
Notes: P* values correspond to the comparison of the deriving and validation groups of HBV-ACLF patients. ND not determined, aP < 0.05 HBV-ACLF vs HCs, bP < 0.05 HBV-ACLF vs CHB, cP < 0.05 HBV-ACLF vs LC, dP < 0.05 HBV-ACLF vs DCC.
Abbreviations: WBC, White blood cell count; ALT, Alanine transaminase; AST, Aspartate transaminase; BUN, blood urea nitrogen; INR, International normalized ratio; MELD, Model for end-stage liver disease.